The estimated Net Worth of Vi Associates, L.P. Dp is at least $1.47 Milione dollars as of 2 June 2011. Vi Dp owns over 6,914 units of Zogenix Inc stock worth over $1,088,277 and over the last 19 years Vi sold ZGNX stock worth over $386,087.
Vi has made over 2 trades of the Zogenix Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently Vi sold 6,914 units of ZGNX stock worth $55,589 on 2 June 2011.
The largest trade Vi's ever made was selling 12,900 units of Zogenix Inc stock on 12 December 2006 worth over $330,498. On average, Vi trades about 3,963 units every 327 days since 2006. As of 2 June 2011 Vi still owns at least 40,790 units of Zogenix Inc stock.
You can see the complete history of Vi Dp stock trades at the bottom of the page.
Vi's mailing address filed with the SEC is C/O DOMAIN ASSOCIATES, LLC, ONE PALMER SQUARE, PRINCETON, NJ, 08542.
Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo e Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: